#1Cooper Companies Investor Presentation January 11, 2022 CooperVision CooperSurgical®#2Cautionary Statements Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding the expected impact of the ongoing COVID-19 pandemic on our business; and statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and diluted earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the "Forward-Looking Statements" section in our press releases and under the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Non-GAAP Financial Measures Certain financial measures included in this presentation, or which may be referred to in management's discussion of the Company's results and outlook, are non-GAAP measures that we believe are helpful in understanding our results, for example, constant currency, adjusted EBITDA, non-GAAP earnings per share and non-GAAP margin results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. The reasons that we use these non-GAAP measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available in our Securities and Exchange Commission filings, including under the "Reconciliation of GAAP Results to Non-GAAP Results" section in our press releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com. CooperCompanies 2#3A Leading Medical Device Company Improving lives one person at a time Industry-leader in Vision and Women's Health Member of the S&P 500 since 2016 FY21 Revenue $2.92B Business Unit Geography CooperSurgical® Women's Health Vision CooperCompanies CooperVision Asia Pacific EMEA Americas 12,000+ Global Workforce 10+ Manufacturing and Distribution Sites 100+ Countries Where Cooper Products Are Sold 3#4CooperCompanies 8.2% annual sales growth from 2016 to 2021 $2,923 $2,533 $2,653 $2,431 $2,139 $1,967 FY16 FY17 FY18 FY19 FY20 FY21 Cooper Companies Note: Sales $ in millions; Annual sales growth is a five-year CAGR 4#5CooperCompanies Fiscal 2022 financial guidance EPS Sales Total FY22 Guidance* Growth vs. FY21 $3,032 $3,090 6% - 8% CC CooperVision $2,225 - $2,267 6% - 8% CC CooperSurgical $807 - $823 6% - 8% CC Non-GAAP $13.60 - $14.00 9.5% 12.5% cc Note: Sales $ in millions; cc means constant currency; Cooper Companies Non-GAAP and cc - Refer to earnings release for definitions and reconciliation of results; *Guidance as initiated 12/2/21. FY22 guidance does not include the Generate Life Sciences acquisition closed 12/17/21. 5#6CooperVision A global leader dedicated to helping improve the way people see each day EVERY DAY. TO ITS FULLEST. CooperVision The moment you tell them about clariti 1 day WA The MyDay daily disposable family. WEAR THE CONTACT LENS OF CONFIDENCE. clariti 1 day Cooper Companies CooperVisio CooperVision Live Brightly. Biofinity Energys The contact lern designed to keep up with your digital lifestyle MiSight 1 day is FDA-approved. BRILLIANT FUTURES" MYOPIA MANAGEMENT PROGRAM 6#7Global Soft Contact Lens Market CooperVision Market by Competitor Market by Category Other CVI 25% 12% Alcon 24% ~$9.4B ~$9.4B JNJ 39% Sphere 66% Cooper Companies Toric 24% Multifocal 10% High Barriers to Entry High capital outlay with highly specialized manufacturing • Technological know-how • Stringent FDA and worldwide regulation Long history of product innovation (SiHy with intellectual property) Favorable Industry Characteristics Strong fundamental growth drivers Underlying wearer growth • Limited reimbursement risk . Recession resistant Annuity business (stickiness) Note: Manufacturers gross sales; Trailing Twelve Months Source: Management estimates and independent market research 7#8The Growing Myopia Epidemic Myopia is expected to affect half the world population by 2050 Myopia Worldwide Prevalence of Myopia 2.6 billion 4.7 billion 50% Why? Increased screen time Less time outdoors MM Genetics 34% 0.9 billion Significant ocular Risks Impaired learning and Impact to quality of health development issues everyday life 22% 0.4 billion High Myopia 2000 2010 2020 2030 2040 2050 Cooper Companies Source: Management estimates and independent market research 8#9Contact Lens Market Drivers Strong fundamental growth drivers New fits/trade-up Shift into 1 Day SiHy lenses ■ Growth in Torics and Multifocals Growing global wearer base Growing prevalence of myopia " 1/3 of the world's population is myopic going to 1/2 by 2050 Geographic expansion - low emerging market penetration Higher net pricing Cooper Companies Source: Management estimates and independent market research 6#10A Global Leader in Myopia Management Broadest portfolio of science-based treatment options addressing the progression of myopia in children Ortho-k MiSight 1 day BRILLIANT FUTURES™ WITH MISIGHT 1 day Only FDA approved myopia control product CooperVision Specialty EyeCare Paragon CooperVision Specialty EyeCare CooperVision Procornea Specialty EyeCare GP Specialists Broad range of market- leading Ortho-k lenses SG SIGHTGLASS VISION Innovative myopia management spectacles Cooper Companies 10#11Ⓡ MiSightⓇ 1 day First and only FDA-approved (1) myopia control contact lens Business Highlights Launching Brilliant FuturesTM Myopia Management Program with MiSightⓇ in multiple countries worldwide including the U.S. Sold as a treatment program by practitioners Investing in myopia management globally including in MiSightⓇ Received regulatory approval in China Growth Drivers (3) Works for nearly all myopic children Cuts myopia progression by roughly 59% on average (2) Works at any age a child starts treatment Works for as long as the child wears it There is no rebound if treatment is stopped CooperCompanies Note: (1) MiSight (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia (nearsightedness) in children with non-diseased eyes, who at the initiation of use are 8-12 years of age and have a refraction of - 0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. (2) When compared to the children in the control group wearing a single vision 1-day contact lens. (3) As confirmed by our industry-leading, 7-year clinical study of MiSight". 11#12CooperVision History of success Durable Sales Growth Annual Sales CAGR 6.4% $2,152 $1,882 $1,973 $1,843 $1,577 $1,674 Outpacing Market Growth Market Share 25% 24% 24% 23% 23% 22% FY16 FY17 FY18 FY19 FY20 FY21 CY15 CY16 CY17 CY18 CY19 CY20 CooperCompanies Note: Sales $ in millions Source: Management estimates and independent market research 12#13CooperVision Revenue by product category and geography FY21 Revenue $2.15B Revenue by Category Revenue by Geography Single- use sphere 29% CooperCompanies Non single-use sphere, other 28% Multifocal 11% EMEA Toric 38% 32% Asia Pacific 23% Americas 39% 13#14CooperVision Well positioned to succeed Products Diverse suite of best-in-class products to fit a wide range of patient needs 1 Day FRP Sphere Toric Multifocal Extended Ranges Toric Multifocal Myopia Management Specialty Silicone Hydrogel Support Relationships Branded and customized solutions Global footprint Logistical and distribution excellence Differentiated Value-Added (C) Services BRILLIANT FUTURES™ eyecarePRIME WITH MISIGHT* 1 day Hydrogel your vision, enabled. CooperCompanies Strong key account relationships Outstanding customer experience 14#15CooperSurgical Healthy women, babies and familiesTM 5 FY21 Revenue $771M Revenue by Category Fertility 41% Office & surgical products Paragard intrauterine copper contraceptive endosee ADVANCE Cooper Companies 59% Cooper Surgical INSORB Skin Stapler Absorbable | Subcuticular 15#16CooperSurgical Fertility portfolio well positioned for success Business Highlights Broadest medical device coverage of the entire IVF cycle(1) Pioneers in IVF genetic testing (state-of-the- art R&D lab) Recently closed Generate Life Science acquisition (12/17/21) Enables new strategic growth opportunities - egg & sperm donation, cryopreservation Increases product offerings, leverages sales force Cooper Companies 1. Fertility Industry Highlights Medical Devices for the IVF Cycle(1) $1.8B+ Global Market¹ 5-10% Annual Growth Fertility Workup Andrology IUI Growth Drivers: Increasing maternal age Greater access to treatment Culture Increased patient awareness/comfort Greater worldwide disposable income Up to 1 in 8 couples suffer from infertility worldwide Manufacturer sales of products and services excluding consultation and pharma Source: Management estimates and independent market research Fertilization Oocyte Retrieval I/H Embryo Biopsy & Testing Cryopreservation Transfer 16#17CooperSurgical Extensive office and surgical platform Business Highlights Produce over 600 clinically-relevant medical devices used by women's health care providers in gynecology and obstetrics Recently closed Generate Life Science acquisition (12/17/21) Expands CSI Labor & Delivery Adds a well-established cord blood and cord tissue storage platform Leverages CSI's highly-respected clinical/professional relationships to cross-sell and advance education Solid recurring revenue stream Industry Highlights Medical Device Drivers: - Shifting to minimally invasive procedures Reimbursement is designed to drive procedures to the office Health systems are looking for partnership relationship with vendors Cord Blood and Cord Tissue Storage Drivers: Advancing stem cell research & therapies increase potential value of storage Cord blood is standard of care alternative to bone marrow transplants for blood disorders¹ Regenerative Medicine potential applications rapidly emerging (lung disease, sports injury, etc.) with 1k+ ongoing clinical studies² Gynecology Obstetrics Office-based providers Labor & Delivery Operating room endosee ADVANCE Paragard intrauterine copper contraceptive cbr Cord deed INSORB Skin Stapler Absorbable | Subcuticular RUMI II SYSTEM CooperCompanies 1. 2. Chao, N. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. In: UpToDate. Negrin,R (Ed), UpToDate, Waltham, MA. https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/Accessed Nov 10, 2021 17#18CooperSurgical Office and surgical - Paragard IUD Business Highlights Only US FDA-approved 100% Hormone Free Intrauterine Device (IUD) Over 99% effective One simple active ingredient - Copper Lasts up to 10 years with Immediate Reversibility In office placement Opportunity to create top of mind awareness IUD Industry Highlights Paragard intrauterine copper contraceptive Non- Hormonal 17% Growth Drivers: ~$1.2B US Market Hormonal 83% Mid-single digit market growth Increased awareness and desire for a non- hormonal product 70% of women are concerned about hormones in birth control Opportunity to shift the U.S. market toward non-hormonal products CooperCompanies Source: Management estimates and independent market research Note: Paragard is included in CooperSurgical's office and surgical products category 18#19CooperSurgical History of success Annual Sales CAGR 14.6% $771 $651 $680 $588 $465 $390 FY16 FY17 FY18 FY19 FY20 FY21 CooperCompanies Note: Sales $ in millions. 19 19#20Socially and Environmentally Responsible Committed to enhancing the health and wellness of people and communities locally and globally Sustainability Clean Energy Resource Conservation Commitment to Recycling IN ENERGY ENVIRONMEN LEED SILVER CooperCompanies SUSTAINABLE UILT ENVIR BREEAM UK CODE FOR AST ONMENT EXCELLENT Our Employees Great Place To WorkⓇ FORTUNE CEO ACT!ON FOR DIVERSITY & INCLUSION Environmental Certifications Certified NOV 2020-NOV 2021 USA BEST LARGE WORKPLACES MANUFACTURING AND PRODUCTION" 2020 MY, Wellness Giving and Community Involvement OPTOMETRY GIVINGSIGHT Mi MARCH OF DIMES 20 20#21Well Positioned for the Future + Operating in two strong markets Revenue growth exceeding our markets Investing in the infrastructure of the business and new products Positioned to achieve long-term objectives Track record of success CooperCompanies 21